Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company active in generics, active pharmaceutical ingredients and selected specialty and biosimilar products. It supplies affordable medicines to patients and healthcare systems across many countries, with a significant presence in the US, India, Russia and other emerging markets. The model combines large-scale manufacturing and regulatory know-how with a growing focus on complex generics and differentiated therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 85,452 | — | 14,178 | — |
| Q3 2025 | 88,051 | — | 14,372 | — |
| Q4 2025 | 87,268 | — | 12,098 | — |
| Q1 2026 | 75,162 | — | 2,209 | — |
| Q2 2026 | 80,705 | -5.6% | 4,435 | -68.7% |
All markets — KeepWinning global stock screener
Other companies on NYSE: Old Republic International Corporation (ORI), Flowserve Corporation (FLS), Universal Health Services, Inc. (UHS), Cullen/Frost Bankers, Inc. (CFR), Pearson plc (PSO), Acuity Inc. (AYI)